4 unchanged sentences
District Court for the Northern District of California against our company and certain of our officers and current and former members of our board of directors, Bergman v.
−Removed: Caribou Biosciences, Inc., et al., Case Number 4:23-cv-01742-YGR (the “Bergman Case”).
+Added: Caribou Biosciences, Inc., et al.
+Added: , Case Number 4:23-cv-01742-YGR (“Bergman Case”).
The Bergman complaint challenges disclosures regarding our company’s business, operations, and prospects, specifically with respect to the alleged durability of CB-010’s therapeutic effect and the product candidate’s clinical and commercial prospects, in alleged violation of Sections 11 and 15 of the Securities Act and Sections 10(b) and 20(a) of the Exchange Act.
On September 18, 2023, plaintiffs filed an amended complaint adding the IPO underwriters as defendants and making substantially the same allegations as the original complaint.
+Added: On November 14, 2023, we filed a motion to dismiss the amended complaint for failure to state a claim.
+Added: Motion to dismiss briefing was completed on February 21, 2024.
+Added: On April 22, 2024, we reached an agreement in principle with plaintiffs to settle the Bergman Case for $3.9 million in exchange for a full release of the putative class’s claims against us and all of our current and former officers, current and former members of our board of directors, the IPO underwriters, and the other named defendant.
+Added: The parties are negotiating a settlement agreement, which the court must approve before settlement is final.
On March 22, 2023, a putative class action lawsuit was filed in Superior Court of the State of California for the County of Alameda against our company and certain of our officers and current and former members of our board of directors, Lowry v.
−Removed: Caribou Biosciences, Inc., et al., Case Number T23-1084 (the “Lowry Case”).
+Added: Caribou Biosciences, Inc., et al.
+Added: , Case Number T23-1084 (“Lowry Case”).
The Lowry Case challenges disclosures regarding our company’s business, operations, and prospects, specifically with respect to the alleged durability of CB-010’s therapeutic effect and the product candidate’s clinical and commercial prospects, in alleged violation of Sections 11 and 15 of the Securities Act.
2 unchanged sentences
On September 11, 2023, plaintiff filed an amended complaint making substantially the same allegations as the original complaint.
−Removed: We believe these lawsuits are without merit and intend to vigorously defend the claims asserted against us.
+Added: On November 9, 2023, we filed a motion to dismiss the amended complaint on the grounds that our certification of incorporation mandates that Securities Act claims against us be brought in federal court.
+Added: On February 28, 2024, the court granted our motion to dismiss and, on April 15, 2024, the court entered an order of dismissal.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.